BioSpace News Archive

Pyramid Biosciences, Inc. today announced the appointment of Brian Lestini, MD, PhD as Chief Executive Officer.

Maze Therapeutics today announced a $190 million financing led by Matrix Capital Management.

Can-Fite BioPharma Ltd announced today that it will hold one-on-one virtual investor meetings during the J.P. Morgan Healthcare Conference.

Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) today announced the signing of a feasibility agreement with Kindeva Drug Delivery to develop Nutriband’s lead product, AVERSA Fentanyl.

The VITAL study, by Professor Pierre Damas and his team, is now published in the well renowned journal Annals of Intensive Care. The study shows a 53% reduction of ventilator-associated pneumonia with Bactiguard’s endotracheal tube.

Collaboration leverages BioNTech’s proprietary multimodal immunotherapy expertise with Crescendo’s proprietary Humabody ® V H platform to develop precision immunotherapies, including mRNA-based antibodies and engineered cell therapies against targets selected by BioNTech BioNTech will hold exclusive worldwide development and commercialization rights to all immunotherapies arising from the collaboration Crescendo will receive $40 million upfront, including a cash payment and an equity in

Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the appointment of Jathin Bandari, M.D., as Chief Medical Officer.

Surrozen, Inc., a company pioneering targeted therapeutics that selectively modulate the Wnt pathway for tissue repair and regeneration, announced key development goals and acceleration of its research pipeline as the company transitions to a clinical-stage biotechnology company.

Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced a clinical trial collaboration and supply agreement with Merck (known as MSD outside the United States and Canada).

Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, provided an overview of the Company’s achievements in 2021 and outlined its objectives for 2022.